Medifast, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Medifast operates the OPTAVIA health and wellness business, primarily selling products through a network of independent coaches. Product sales represented approximately 98% of revenue.
Financial performance
| Metric | Q2 2022 | Q2 2021 | H1 2022 | H1 2021 |
|---|---|---|---|---|
| Revenue | $453.3M | $394.2M | $870.9M | $734.9M |
| Gross margin | 71.0% | 74.5% | 71.6% | 73.8% |
| Operating income | $49.0M | $61.4M | $104.1M | $114.2M |
| Net income | $39.1M | $47.0M | $80.9M | $88.0M |
| Diluted EPS | $3.42 | $3.96 | $7.01 | $7.42 |
| Operating cash flow | — | — | $87.4M | $86.2M |
Revenue grew 15.0% in Q2 and 18.5% in H1. Management attributed growth primarily to more active earning coaches and greater productivity per coach. The Q2 coach count rose 14.9% year over year to 68,000.
Profitability declined despite revenue growth: Q2 operating income fell 20.3% and net income fell 16.7%; H1 operating income fell 8.9% and net income fell 8.1%. Cost of sales rose faster than revenue, reflecting product-cost inflation in ingredients and labor and greater use of co-manufacturers. SG&A also increased, including coach compensation, technology and distribution investment, and higher credit-card fees.
Liquidity, debt and capital allocation
- At June 30, cash and cash equivalents were $61.1M, versus $104.2M at year-end 2021; investment securities were zero, versus $5.4M. Working capital was $55.1M, down from $137.0M.
- Current assets were $243.3M and current liabilities $188.2M. Total liabilities were $211.1M; stockholders’ equity was $129.5M.
- H1 operating cash flow was $87.4M; investing cash outflow was $0.6M and financing cash outflow was $130.1M. Financing outflows included $100.0M for an accelerated share repurchase and $35.6M of dividends paid.
- The amended credit agreement provides a $225M senior secured revolving facility, plus a conditional incremental facility of up to $100M. Borrowings were $27.0M at quarter-end; the company reported compliance with its debt covenants. The facility matures April 2026.
- The company declared a $1.64-per-share quarterly dividend and said it intends to continue dividends, while cautioning it cannot assure future payments. The $100M ASR had delivered about 480,000 shares by quarter-end, with the remaining shares expected by October 3, 2022.
Material changes, outlook and risks
- Gross margin and operating margin contracted: Q2 operating margin was 10.8%, versus 15.6% a year earlier; H1 was 11.9%, versus 15.5%.
- The company donated inventory costing $9.4M to organizations supporting Ukrainian refugees. This increased Q2 SG&A. Management also presented non-GAAP results excluding the donation; Q2 adjusted diluted EPS was $3.87 versus GAAP EPS of $3.42. These non-GAAP measures are supplemental, not replacements for GAAP results.
- The filing gives no specific financial guidance or quantified outlook. Management described continued investment in the OPTAVIA community, technology and distribution infrastructure, and stated it expects the business model to support future growth.
- Key operating pressures include ingredient and labor inflation, reliance on co-manufacturers as demand accelerates, and the ability to sustain coach growth and productivity. The filing also notes potential future COVID-19 effects on operations, suppliers and consumer behavior, though no meaningful supply-chain disruption had been experienced to date.
- Ordinary-course legal proceedings were not believed by the company to have a material adverse effect, but outcomes are uncertain. The company reported no material changes to the risk factors in its 2021 Form 10-K.
Important facts for investors to verify
- Whether revenue and coach-network growth can continue while gross and operating margins recover from inflation and higher selling costs.
- The subsequent share delivery and final settlement of the $100M ASR, and the effects of repurchases on cash, equity and per-share results.
- Cash generation and liquidity after dividends, repurchases and ongoing investment; also review revolver terms, interest-rate exposure and covenant headroom.
- Whether the $9.4M Ukraine donation and its tax effects are treated consistently when comparing GAAP and company-adjusted results.
- Any later updates on supply-chain conditions, co-manufacturer usage, coach productivity, and legal or other contingencies.